‘Gilead’s deal with Indian generic drug companies will help earn goodwill for the industry’

Sofosbuvir is considered a revolutionary treatment for Hepatitis C as it has a high cure rate. Gilead’s deal allows the generic manufacturers to sell in 91 countries.

September 16, 2014 09:00 pm | Updated November 16, 2021 05:48 pm IST - MUMBAI:

Sofosbuvir is considered a revolutionary treatment for Hepatitis C as it has a high cure rate. Gilead’s deal with seven Indian pharmaceutical companies allows the generic manufacturers to sell the drug in 91 countries. File photo

Sofosbuvir is considered a revolutionary treatment for Hepatitis C as it has a high cure rate. Gilead’s deal with seven Indian pharmaceutical companies allows the generic manufacturers to sell the drug in 91 countries. File photo

The signing of agreements by U.S. pharmaceutical giant Gilead with seven Indian generic drug manufacturers, licensing them to make its blockbuster drug sofosbuvir for treatment of killer disease Hepatitis C could be a show-case of how innovative and generic companies could work together for access to affordable medicines, Indian Pharmaceutical Alliance (IPA) Secretary-General D. G. Shah said here on Tuesday.

“I welcome this change, and believe that together generic and innovative industry can make wonders and earn goodwill for the much maligned pharmaceutical industry,’’ he added.

Sofosbuvir is considered a revolutionary treatment for Hepatitis C as it has a high cure rate. Gilead’s deal allows the generic manufacturers to sell in 91 countries.

“Gilead’s licensing terms fall far short of ensuring widespread affordable access to these new drugs in middle-income countries, where over 70 per cent of people with Hepatitis C live today,’’ Rohit Malpani, Director of Policy & Analysis, Medicins Sans Frontieres (MSF) Access Campaign, said in a statement.

“We welcome the interest of generic companies to scale up production of new direct-acting antivirals (DAAs) and Gilead’s decision to make the final agreement public; however, a highly restrictive voluntary licence that blocks millions of people with Hepatitis C from affordable prices is not acceptable,’’ Mr. Malpani said.

While the drug regimen is sold at $ 84,000 in the U.S. and $50,000 in France, Indian generic manufacturers have the discretion to determine their selling price. Mr. Shah said Gilead had no restrictions regarding quantum of production “and they have not determined selling price and have offered the technology transfer. Generic manufacturers are aware about the price sensitivity of a market like India and will surely price the drug accordingly.’’

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.